{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,2]],"date-time":"2022-04-02T00:04:27Z","timestamp":1648857867212},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,4,26]],"date-time":"2013-04-26T00:00:00Z","timestamp":1366934400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Endocrine"],"published-print":{"date-parts":[[2013,8]]},"DOI":"10.1007\/s12020-013-9954-6","type":"journal-article","created":{"date-parts":[[2013,4,30]],"date-time":"2013-04-30T22:20:25Z","timestamp":1367360425000},"page":"5-7","source":"Crossref","is-referenced-by-count":1,"title":["Is there a role for combination therapy for osteoporosis?"],"prefix":"10.1007","volume":"44","author":[{"given":"Felicia","family":"Cosman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,4,26]]},"reference":[{"key":"9954_CR1","doi-asserted-by":"crossref","unstructured":"Walker, M.D., Cusano, N.E., Sliney, J., Jr., Romano, M., Zhang, C., McMahon, D.J., Bilezikian, J.P.: Combination therapy with risedronate and teriparatide in male osteoporosis. Endocrine (2012). doi: 10.1007\/s12020-012-9819-4","DOI":"10.1007\/s12020-012-9819-4"},{"issue":"1","key":"9954_CR2","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s12020-011-9554-2","volume":"41","author":"J Compston","year":"2012","unstructured":"J. Compston, The use of combination therapy in the treatment of postmenopausal osteoporosis. Endocrine 41(1), 11\u201318 (2012). doi: 10.1007\/s12020-011-9554-2","journal-title":"Endocrine"},{"issue":"1","key":"9954_CR3","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s12020-011-9570-2","volume":"41","author":"G Mazziotti","year":"2012","unstructured":"G. Mazziotti, J. Bilezikian, E. Canalis, D. Cocchi, A. Giustina, New understanding and treatments for osteoporosis. Endocrine 41(1), 58\u201369 (2012). doi: 10.1007\/s12020-011-9570-2","journal-title":"Endocrine"},{"issue":"5","key":"9954_CR4","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1359\/jbmr.040117","volume":"19","author":"B Ettinger","year":"2004","unstructured":"B. Ettinger, J. San Martin, G. Crans, I. Pavo, Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J. Bone Miner. Res. 19(5), 745\u2013751 (2004). doi: 10.1359\/JBMR.040117","journal-title":"J. Bone Miner. Res."},{"issue":"10","key":"9954_CR5","doi-asserted-by":"crossref","first-page":"3785","DOI":"10.1210\/jc.2008-0353","volume":"93","author":"PD Miller","year":"2008","unstructured":"P.D. Miller, P.D. Delmas, R. Lindsay, N.B. Watts, M. Luckey, J. Adachi, K. Saag, S.L. Greenspan, E. Seeman, S. Boonen, S. Meeves, T.F. Lang, J.P. Bilezikian, Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate. J. Clin. Endocrinol. Metab. 93(10), 3785\u20133793 (2008). doi: 10.1210\/jc.2008-0353","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"3","key":"9954_CR6","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1210\/jc.2007-0711","volume":"93","author":"S Boonen","year":"2008","unstructured":"S. Boonen, F. Marin, B. Obermayer-Pietsch, M.E. Simoes, C. Barker, E.V. Glass, P. Hadji, G. Lyritis, H. Oertel, T. Nickelsen, E.V. McCloskey, Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis. J. Clin. Endocrinol. Metab. 93(3), 852\u2013860 (2008)","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"6","key":"9954_CR7","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1056\/NEJMoa050157","volume":"353","author":"F Cosman","year":"2005","unstructured":"F. Cosman, J. Nieves, M. Zion, L. Woelfert, M. Luckey, R. Lindsay, Daily and cyclic parathyroid hormone in women receiving alendronate. N. Engl. J. Med. 353(6), 566\u2013575 (2005)","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"9954_CR8","doi-asserted-by":"crossref","first-page":"3772","DOI":"10.1210\/jc.2008-2719","volume":"94","author":"F Cosman","year":"2009","unstructured":"F. Cosman, R.A. Wermers, C. Recknor, K.F. Mauck, L. Xie, E.V. Glass, J.H. Krege, Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: differences between stopping and continuing the antiresorptive agent. J. Clin. Endocrinol. Metab. 94(10), 3772\u20133780 (2009). doi: 10.1210\/jc.2008-2719","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"9954_CR9","doi-asserted-by":"crossref","unstructured":"Cosman, F., Keaveny, T.M., Kopperdahl, D., Wermers, R.A., Wan, X., Krohn, K.D., Krege, J.H.: Hip and spine strength effects of adding versus switching to teriparatide in postmenopausal women with osteoporosis treated with prior alendronate or raloxifene. J. Bone Miner. Res. n\/a-n\/a (2012). doi: 10.1002\/jbmr.1853","DOI":"10.1002\/jbmr.1853"},{"issue":"13","key":"9954_CR10","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa031975","volume":"349","author":"DM Black","year":"2003","unstructured":"D.M. Black, S.L. Greenspan, K.E. Ensrud, L. Palermo, J.A. McGowan, T.F. Lang, P. Garnero, M.L. Bouxsein, J.P. Bilezikian, C.J. Rosen, T.H.S.I. Pa, The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N. Eng. J. Med. 349(13), 1207\u20131215 (2003). doi: 10.1056\/NEJMoa031975","journal-title":"N. Eng. J. Med."},{"issue":"3","key":"9954_CR11","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1002\/jbmr.238","volume":"26","author":"F Cosman","year":"2011","unstructured":"F. Cosman, E.F. Eriksen, C. Recknor, P.D. Miller, N. Guanabens, C. Kasperk, P. Papanastasiou, A. Readie, H. Rao, J.A. Gasser, C. Bucci-Rechtweg, S. Boonen, Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1\u201334)] in postmenopausal osteoporosis. J. Bone Miner. Res. 26(3), 503\u2013511 (2011). doi: 10.1002\/jbmr.238","journal-title":"J. Bone Miner. Res."},{"issue":"11","key":"9954_CR12","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1359\/JBMR.050714","volume":"20","author":"C Deal","year":"2005","unstructured":"C. Deal, M. Omizo, E.N. Schwartz, E.F. Eriksen, P. Cantor, J. Wang, E.V. Glass, S.L. Myers, J.H. Krege, Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial. J. Bone Miner. Res. 20(11), 1905\u20131911 (2005). doi: 10.1359\/JBMR.050714","journal-title":"J. Bone Miner. Res."},{"issue":"1","key":"9954_CR13","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1002\/jbmr.1716","volume":"28","author":"C Muschitz","year":"2013","unstructured":"C. Muschitz, R. Kocijan, A. Fahrleitner-Pammer, S. Lung, H. Resch, Antiresorptives overlapping ongoing teriparatide treatment result in additional increases in bone mineral density. J. Bone Miner. Res. 28(1), 196\u2013205 (2013). doi: 10.1002\/jbmr.1716","journal-title":"J. Bone Miner. Res."},{"issue":"1","key":"9954_CR14","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1359\/jbmr.2003.18.1.9","volume":"18","author":"ES Orwoll","year":"2003","unstructured":"E.S. Orwoll, W.H. Scheele, S. Paul, S. Adami, U. Syversen, A. Diez-Perez, J.M. Kaufman, A.D. Clancy, G.A. Gaich, The effect of teriparatide [human parathyroid hormone (1\u201334)] therapy on bone density in men with osteoporosis. J. Bone Miner. Res. 18(1), 9\u201317 (2003). doi: 10.1359\/jbmr.2003.18.1.9","journal-title":"J. Bone Miner. Res."},{"issue":"1","key":"9954_CR15","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1359\/jbmr.2003.18.1.18","volume":"18","author":"R Marcus","year":"2003","unstructured":"R. Marcus, O. Wang, J. Satterwhite, B. Mitlak, The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis. J. Bone Miner. Res. 18(1), 18\u201323 (2003). doi: 10.1359\/jbmr.2003.18.1.18","journal-title":"J. Bone Miner. Res."}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-013-9954-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12020-013-9954-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-013-9954-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T01:56:48Z","timestamp":1559440608000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12020-013-9954-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4,26]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,8]]}},"alternative-id":["9954"],"URL":"https:\/\/doi.org\/10.1007\/s12020-013-9954-6","relation":{},"ISSN":["1355-008X","1559-0100"],"issn-type":[{"value":"1355-008X","type":"print"},{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,4,26]]}}}